降剂量对早期口咽癌患者报告结局的影响:ORATOR研究二次分析
该事后分析纳入ORATOR和ORATOR2试验中接受根治性放疗的59例p16阳性T1-T2口咽鳞癌患者,比较60 Gy与70 Gy两组的患者报告结局和毒性。结果显示60 Gy组在1年时吞咽功能及多个生活质量领域显著更优,且2-3级吞咽困难和黏膜炎发生率显著更低。
要点
- 60 Gy组1年MDADI总分和功能评分较70 Gy组显著改善
- 60 Gy组多个EORTC生活质量领域及口干、唾液黏稠等症状显著更优
- 60 Gy组2-3级吞咽困难和2-3级黏膜炎发生率显著更低
核心结论
- 对p16阳性早期口咽鳞癌,从70 Gy降至60 Gy可能改善多个领域的患者报告结局并降低毒性。
- 两项剂量直接比较的结果尚待报告。
研究设计与样本
- ORATOR和ORATOR2随机试验的事后二次分析,纳入接受根治性放疗的p16阳性口咽鳞癌患者。
- 共59例,60 Gy组29例(ORATOR2,多每周顺铂),70 Gy组30例(ORATOR,多每3周顺铂)。
- 比较患者报告结局、生活质量、毒性、总生存和无进展生存。
主要发现
- 1年时60 Gy组MDADI总分变化为+1.9±12.2,70 Gy组为-5.8±11.3(P=.035)。
- 1年时60 Gy组MDADI功能评分变化为+5.5±12.7,70 Gy组为-3.3±12.2(P=.023)。
- 60 Gy组在EORTC全局健康状况、疲乏、恶心呕吐、食欲、便秘、疼痛、口干、唾液黏稠和咳嗽等领域1年结局显著更优(均P<.05)。
- 60 Gy组2-3级吞咽困难和2-3级黏膜炎发生率显著更低(均P<.05)。
临床怎么用
- 对于p16阳性早期口咽鳞癌接受根治性放疗者,60 Gy方案可能改善吞咽相关患者报告结局并降低黏膜炎和吞咽困难毒性。
- 临床决策仍需等待两项剂量直接比较的随机试验结果。
局限性
- 为两项独立试验的事后二次分析,非直接随机比较,样本量59例较小。
- 两组全身治疗模式不同(70 Gy组多每3周顺铂,60 Gy组多每周顺铂),可能混杂结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluates the impact of treatment de-escalation from 70 to 60 Gy on patient-reported outcomes (PROs) and toxicity for patients with T1-2 p16-positive oropharyngeal squamous cell carcinoma (OPSCC) treated with primary radiation therapy as part of the ORATOR and ORATOR2 trials. METHODS AND MATERIALS: Patients with p16-positive OPSCC treated with primary radiation therapy in the ORATOR randomized trials were included in this post hoc analysis. Patient demographics, tumor and treatment characteristics were compared between patients who received radiation with 70 Gy (ORATOR, usually with cisplatin every 3 weeks) versus 60 Gy (ORATOR2, usually with weekly cisplatin). Outcomes examined included PROs and quality of life (QOL) metrics, including the MD Anderson Dysphagia Inventory, European Organization for Research and Treatment of Cancer Quality of Life Core 30 (C30) and Head and Neck 35 (H&N35) scales, toxicity, overall survival, and progression-free survival. RESULTS: The cohort included 59 patients, of whom 29 patients treated with 60 Gy and 30 patients with 70 Gy. Comparing QOL changes at 1 year in the 60- and 70-Gy cohorts, respectively, the 60-Gy cohort demonstrated improved MD Anderson Dysphagia Inventory total (mean ± SD change: +1.9 ± 12.2 vs -5.8 ± 11.3; P = .035), and functional (+5.5 ± 12.7 vs -3.3 ± 12.2; P = .023) scores. The 60-Gy cohort demonstrated significantly better outcomes at 1 year in several European Organization for Research and Treatment of Cancer QOL domains: global health status, fatigue, nausea/vomiting, appetite, constipation, pain, xerostomia, sticky saliva, and coughing (all P < .05). Patients treated with 60 Gy had significantly lower rates of grade 2-3 dysphagia and grade 2-3 mucositis (all P < .05). CONCLUSIONS: This comparison of arms from the separate ORATOR trials suggests that de-escalation from 70 to 60 Gy for p16-positive patients with early-stage OPSCC may lead to better PROs across numerous domains and reduced toxicity. Results from direct comparisons of these 2 doses are awaited.
引用
- Dang A, Palma DA, Nichols AC, et al. What Is the Impact of Treatment De-Escalation on Patient-Reported Outcomes in Patients With T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR Studies. Int J Radiat Oncol Biol Phys. 2026. PMID: 42349663. doi:10.1016/j.ijrobp.2026.06.3054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。